clinical trial · NCT06921850
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
UCB Biopharma SRL·phase3·active not recruiting·n = 43
Hidradenitis SuppurativaBimekizumab
brief summary
The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
started
Apr 7, 2025
primary completion
Dec 21, 2026
completion
Mar 6, 2029
last updated
Sep 11, 2026
official title
A Multicenter, Open-Label Study to Assess The Pharmacokinetics And Safety of Bimekizumab in Pubertal Children And Adolescents With Moderate to Severe Hidradenitis Suppurativa
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol